Abivax presents third quarter 2024 key financial information

Abivax presents third quarter 2024 key financial information paris, france, november 14, 2024, 10:00 p.m. cet – abivax sa (euronext paris: fr0012333284 – abvx / nasdaq – abvx) (“abivax” or the “company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial information for the quarter ended september 30, 2024.
ABVX Ratings Summary
ABVX Quant Ranking